MX2022006529A - Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a contaminantes del aire. - Google Patents
Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a contaminantes del aire.Info
- Publication number
- MX2022006529A MX2022006529A MX2022006529A MX2022006529A MX2022006529A MX 2022006529 A MX2022006529 A MX 2022006529A MX 2022006529 A MX2022006529 A MX 2022006529A MX 2022006529 A MX2022006529 A MX 2022006529A MX 2022006529 A MX2022006529 A MX 2022006529A
- Authority
- MX
- Mexico
- Prior art keywords
- air pollutants
- composition
- nasal
- silicon dioxide
- risks
- Prior art date
Links
- 239000000809 air pollutant Substances 0.000 title abstract 4
- 231100001243 air pollutant Toxicity 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 4
- 229910021426 porous silicon Inorganic materials 0.000 abstract 4
- 235000012239 silicon dioxide Nutrition 0.000 abstract 4
- 239000000377 silicon dioxide Substances 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000004888 barrier function Effects 0.000 abstract 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se describen métodos para reducir los riesgos de la exposición a contaminantes del aire, que comprenden administrar por vía nasal a un sujeto que lo necesita una composición que contrarresta los efectos de uno o más contaminantes del aire, en donde la composición está adaptada para la administración nasal. En algunas formas de realización, la composición comprende un agente que se fija a uno o más contaminantes del aire, en donde el agente comprende uno o ambos de dióxido de silicio no poroso y dióxido de silicio poroso y/o la composición proporciona una barrera física entre uno o más contaminantes del aire y las superficies nasales internas. En la presente también se describen composiciones nasales que comprenden un agente que comprende uno o ambos de dióxido de silicio no poroso y dióxido de silicio poroso, un vehículo lipofílico o parcialmente lipofílico, y un tensioactivo, en donde la composición está adaptada para la administración nasal. En la presente también se describen métodos para fabricar y utilizar composiciones farmacéuticas nasales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448556P | 2017-01-20 | 2017-01-20 | |
| US201762517369P | 2017-06-09 | 2017-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006529A true MX2022006529A (es) | 2022-07-11 |
Family
ID=61094560
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008656A MX394742B (es) | 2017-01-20 | 2018-01-19 | Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a los contaminantes del aire |
| MX2022006529A MX2022006529A (es) | 2017-01-20 | 2019-07-19 | Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a contaminantes del aire. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008656A MX394742B (es) | 2017-01-20 | 2018-01-19 | Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a los contaminantes del aire |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10729646B2 (es) |
| EP (1) | EP3570848B1 (es) |
| KR (1) | KR20190109452A (es) |
| CN (1) | CN110461340A (es) |
| CA (1) | CA3050361A1 (es) |
| ES (1) | ES2948282T3 (es) |
| HU (1) | HUE063346T2 (es) |
| MX (2) | MX394742B (es) |
| RU (1) | RU2019123307A (es) |
| SG (1) | SG11201906616VA (es) |
| WO (1) | WO2018134783A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201810628XA (en) | 2016-06-03 | 2018-12-28 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
| CN111902188A (zh) | 2018-01-11 | 2020-11-06 | 马特恩制药股份公司 | 脱髓鞘疾病的治疗 |
| KR102817716B1 (ko) | 2019-09-04 | 2025-06-05 | 엘지디스플레이 주식회사 | 유기 화합물, 이를 포함하는 유기발광다이오드 및 유기발광장치 |
| US20210275989A1 (en) * | 2020-03-05 | 2021-09-09 | Performance Labs PTE. LTD. | Functional materials and devices for reducing toxic pollutants |
| CN116600787A (zh) * | 2020-11-19 | 2023-08-15 | 阿库西亚医疗有限责任公司 | 非水性凝胶组合物 |
| CN114653172B (zh) * | 2022-03-15 | 2023-11-14 | 江苏理工学院 | 一种协同脱除VOCs和Hg0的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4546882A (en) | 1983-02-07 | 1985-10-15 | American Can Company | Package having oil-containing product |
| US5002597A (en) * | 1989-04-03 | 1991-03-26 | Invent Ag | Aerodynamic filter |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| DE19701912C1 (de) | 1997-01-10 | 1998-05-14 | Jenapharm Gmbh | Injizierbares Implantat |
| DE10064950A1 (de) * | 2000-12-23 | 2002-07-11 | Impetus Ag Basel | Thixotropes Nasenspray |
| US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| US7563451B2 (en) | 2003-07-22 | 2009-07-21 | Iowa State University Research Foundation, Inc. | Capped mesoporous silicates |
| DE60303854T2 (de) | 2003-11-11 | 2006-08-10 | Mattern, Udo | Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen |
| US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
| US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
| US20070077309A1 (en) | 2005-09-30 | 2007-04-05 | Wong Patrick S | Banded controlled release nanoparticle active agent formulation dosage forms and methods |
| JP5248510B2 (ja) | 2006-10-04 | 2013-07-31 | エム アンド ペー パテント アクツィエンゲゼルシャフト | 神経伝達物質の鼻腔投与のための徐放性送達システム |
| US8258137B2 (en) | 2008-01-29 | 2012-09-04 | Katholieke Universiteit Leuven | Process for release of biologically active species from mesoporous oxide systems |
| JP5730316B2 (ja) | 2008-09-23 | 2015-06-10 | ラボラトリー スキン ケア インコーポレイテッド | 活性剤を充填した、均一、硬質、球状のナノ多孔質リン酸カルシウム粒子の製造方法 |
| JP2010083834A (ja) * | 2008-10-01 | 2010-04-15 | Naris Cosmetics Co Ltd | アレルゲン不活性化剤、及びそれを含有する化粧料。 |
| WO2010050897A1 (en) | 2008-10-28 | 2010-05-06 | Agency For Science, Technology And Research | Mesoporous material excipients for poorly aqueous soluble ingredients |
| CA2835911C (en) * | 2011-05-13 | 2022-08-30 | Trimel Biopharma Srl | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US20130040922A1 (en) * | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| MX363561B (es) * | 2011-05-15 | 2019-03-27 | Trimel Biopharma Srl | Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal. |
| ES2740958T5 (en) * | 2012-02-27 | 2025-04-03 | Elanco New Zealand | Controlled release compositions and their methods of use |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| WO2014080283A2 (en) | 2012-11-21 | 2014-05-30 | Trimel Biopharma Srl | Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt |
| WO2015066717A1 (en) | 2013-11-04 | 2015-05-07 | BioPharmX, Inc. | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers |
| EP3193836A1 (en) | 2014-09-15 | 2017-07-26 | PharmaSol GmbH | Active-loaded particulate materials for topical administration |
| US11123391B2 (en) * | 2015-08-04 | 2021-09-21 | Inqpharm Group Sdn Bhd | Nasal composition |
| US20180250656A1 (en) * | 2015-09-09 | 2018-09-06 | King Abdullah University Of Science And Technology | Functionalized sio2 microspheres for extracting oil from produced water |
| SG11201810628XA (en) | 2016-06-03 | 2018-12-28 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
-
2018
- 2018-01-19 WO PCT/IB2018/050349 patent/WO2018134783A1/en not_active Ceased
- 2018-01-19 ES ES18702341T patent/ES2948282T3/es active Active
- 2018-01-19 KR KR1020197023918A patent/KR20190109452A/ko not_active Ceased
- 2018-01-19 RU RU2019123307A patent/RU2019123307A/ru unknown
- 2018-01-19 CN CN201880019834.3A patent/CN110461340A/zh active Pending
- 2018-01-19 CA CA3050361A patent/CA3050361A1/en active Pending
- 2018-01-19 MX MX2019008656A patent/MX394742B/es unknown
- 2018-01-19 EP EP18702341.1A patent/EP3570848B1/en active Active
- 2018-01-19 SG SG11201906616VA patent/SG11201906616VA/en unknown
- 2018-01-19 HU HUE18702341A patent/HUE063346T2/hu unknown
- 2018-06-22 US US16/016,335 patent/US10729646B2/en active Active
-
2019
- 2019-07-19 MX MX2022006529A patent/MX2022006529A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180296472A1 (en) | 2018-10-18 |
| CA3050361A1 (en) | 2018-07-26 |
| MX394742B (es) | 2025-03-12 |
| RU2019123307A3 (es) | 2021-05-24 |
| ES2948282T3 (es) | 2023-09-07 |
| EP3570848B1 (en) | 2023-06-07 |
| CN110461340A (zh) | 2019-11-15 |
| HUE063346T2 (hu) | 2024-01-28 |
| RU2019123307A (ru) | 2021-02-20 |
| SG11201906616VA (en) | 2019-08-27 |
| EP3570848A1 (en) | 2019-11-27 |
| EP3570848C0 (en) | 2023-06-07 |
| WO2018134783A1 (en) | 2018-07-26 |
| MX2019008656A (es) | 2019-11-21 |
| US10729646B2 (en) | 2020-08-04 |
| KR20190109452A (ko) | 2019-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006529A (es) | Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a contaminantes del aire. | |
| MX2018014906A (es) | Composiciones farmaceuticas nasales con un excipiente poroso. | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| ECSP18017254A (es) | Composiciones con potenciadores de permeación para suministro de fármacos | |
| CL2018001270A1 (es) | Mezcla de tabaco | |
| CL2023000524A1 (es) | Compuestos fosfolípidos y usos de los mismos | |
| MX2015009772A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| CL2019001244A1 (es) | Mezcla de tabaco. | |
| PE20211069A1 (es) | Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina | |
| MX2019009271A (es) | Portador de sustancia fisiologicamente activa. | |
| DOP2023000074A (es) | Compuestos fosfolípidos y usos de estos | |
| MX2018014202A (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
| CO2019000945A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| CL2011003327A1 (es) | Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales. | |
| CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
| CL2017001718A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
| CO2019000943A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| CL2013002700A1 (es) | Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros | |
| MX2017004828A (es) | Composicion oftalmica que comprende ciclosporina y trehalosa. | |
| CY1125375T1 (el) | Ενα λυοφιλοποιημενο φαρμακευτικο σκευασμα και η χρηση του | |
| MX2016014256A (es) | Formulaciones y metodos para el suministro vaginal de antiprogestinas. | |
| CO2018002428A2 (es) | Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol |